Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Therapy IIIB for Newly Diagnosed Multiple Myeloma
NCT00572169Phase 3Active, not recruiting
- Sponsor
- University of Arkansas
- Start
- Nov 2006
- Primary completion
- Aug 2027
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by University of Arkansas. Primary endpoint: Outcomes compared to Total Therapy II at 48 months. Started Nov 2006; status: active, not recruiting.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00572169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00572169.